The efficacy and safety of transcatheter arterial chemoembolization combined with Endostar for primary hepatocellar carcinoma

Objective:To investigate the efficacy and safety of combined therapy of transcatheter arterial chemoembolization with Endostar for primary hepatocellular carcinoma.Methods:Fifty patients with hepatocellar carcinoma were given the combined therapy of transcatheter arterial chemoembolization with Endostar.The adverse reaction and short-term efficacy were evaluated after the combined therapy to evaluate the safety and efficacy of the combined therapy.Results:After the 50 patients with hepatocellar carcinoma received the combined therapy of transcatheter arterial chemoembolization with Endostar,the mainly observed adverse effects were Ⅰ to Ⅱ degree neutropenia and elevation in hepatic enzymes.No severe adverse effects were observed in our study.The results of short-term efficacy showed that among the 50 patients with hepatocellular carcinoma 3 had partial response(PR),40 had stable disease(SD),and 7 had progressive disease(PD).Disease control rate(DCR) was 86.0%.Conclusion:Transcatheter arterial chemoembolization combined with Endostar was safe and effective in the treatment of primary hepatocellular carcinoma.